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Background: Randomized control trials (RCTs) stopped early for benefit (truncated RCTs) are increasingly common
and, on average, overestimate the relative magnitude of benefit by approximately 30%. Investigators stop trials early
when they consider it is no longer ethical to enroll patients in a control group. The goal of this systematic review is
to determine how investigators of ongoing or planned RCTs respond to the publication of a truncated RCT
addressing a similar question.
Methods/design: We will conduct systematic reviews to update the searches of 210 truncated RCTs to identify
similar trials ongoing at the time of publication, or started subsequently, to the truncated trials (‘subsequent RCTs’).
Reviewers will determine in duplicate the similarity between the truncated and subsequent trials. We will analyze
the epidemiology, distribution, and predictors of subsequent RCTs. We will also contact authors of subsequent trials
to determine reasons for beginning, continuing, or prematurely discontinuing their own trials, and the extent to
which they rely on the estimates from truncated trials.
Discussion: To the extent that investigators begin or continue subsequent trials they implicitly disagree with the
decision to stop the truncated RCT because of an ethical mandate to administer the experimental treatment. The
results of this study will help guide future decisions about when to stop RCTs early for benefit.
Keywords: Randomized controlled trials stopped early for benefit, RCT, Systematic review, ProtocolBackground
The decision of whether to stop a randomized control
trial (RCT) for apparent benefit before its planned com-
pletion is complex and requires consideration of ethical,
statistical, and practical issues [1]. The main rationale
for stopping is to avoid denying current and future* Correspondence: jpdomecq@gmail.com
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reproduction in any medium, provided the orcontrol group participants a beneficial treatment, and
to ensure rapid dissemination of that treatment [2]. A
correct decision requires the wise judgment of the
study investigators and, preferably, of an independent
data monitoring committee (DMC) typically including
trialists with both clinical and statistical expertise [3].
The DMC needs to attend to the interests of future pa-
tients and society at large, while considering the impact
of their results on the wider community of clinicians,
researchers, and evidence users [2]. Considerations in-
clude the risk of disseminating an overestimation of the
treatment effect on the primary outcome and ensuringLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Prutsky et al. Trials 2013, 14:335 Page 2 of 8
http://www.trialsjournal.com/content/14/1/335that the optimal information regarding toxicity and
secondary outcomes is also captured, particularly if ad-
verse events occur late in the course of the trial [4].
A systematic review (Study of Trial Policy of Interim
Truncation-1 (STOPIT-1)) developed by our group to
evaluate the epidemiology and reporting quality of RCTs
stopped early for benefit (truncated RCTs (tRCTs))
found that this type of trial was becoming more com-
mon, and often failed to adequately report relevant in-
formation about the decision to stop early [5]. A
subsequent systematic review (STOPIT-2) compared 91
tRCTs asking 63 different research questions to 424
non-tRCTs asking similar questions. tRCTs tended to
overestimate the magnitude of benefit by one third
(average), regardless of the use of statistical stopping
rules. Moreover, almost two thirds of the pooled effects
of the non-tRCTs failed to demonstrate benefit [6].
These results raise serious concerns about the poten-
tial impact of stopping trials early on the body of evi-
dence and therefore on current health policies. First,
investigators have disseminated an estimate of effect that
is, on average, substantially overestimated; how stake-
holders best incorporate this evidence in generating sub-
sequent best estimates of effect is uncertain. Second, this
represents a lost opportunity to generate more precise
and higher quality evidence about benefits and harms.
Third, the publication of a trial stopped early for benefit
may stop further research addressing the same question,
which may distort the effect size (overestimating the ef-
fect and making it more imprecise) of the whole body of
evidence [7].
There are a number of possible reasons investigators
launch a new study with a similar research question to
that of a tRCT, or continue one in progress (we shall
refer to trials continued or started despite a previous
tRCT as ‘subsequent RCTs’ (sRCTs). First, they may be
unaware of the existence of the tRCTs. This seems un-
likely, given that researchers are usually aware of on-
going research in their field, and that tRCTs are
commonly published in high impact journals, and often
receive appreciable media attention [5,6]. A second pos-
sibility is that investigators are aware of the findings of
the tRCT but remain unconvinced of the observed large
benefit (even of whether there is any important benefit)
and thus deem it ethical to allocate patients to not re-
ceive the new treatment. The decision to continue a
current trial or start a new one answering a similar re-
search question may represent an implicit different judg-
ment with the previous decision to stop early and to the
body of evidence in general.
If sRCTs are common, it suggests that current practice
of stopping RCTs for apparent benefit might not be ac-
ceptable by many other scientists and not sufficiently
conservative either by reaching different conclusionsthan the body of evidence or showing highly unreliable
estimates. Understanding the decisions to initiate, con-
tinue, or begin sRCTs is likely to provide insights that
ultimately improve the policies and procedures of clin-
ical trial oversight and the credibility of clinical research.
Objective
The present study aims to examine how often random-
ized trials are launched or continued after the publica-
tion of a tRCT asking the same or sufficiently similar
research question. We will also analyze trials that were
stopped in response to such external evidence. Our
study involved two primary research questions. First,
what is the proportion of tRCTs that are followed by a
sRCT addressing the same or closely similar research
question? Second, what factors/rationale are associated
with the launching or continuation of a sRCT after the
publication of a tRCT?
Methods/design
Overview of methods
The design and findings of STOPIT-1, 2, and 3 are
depicted in Figure 1. STOPIT-1 included 143 tRCTs.
During the development of STOPIT-2, researchers iden-
tified 14 additional tRCTs through hand search and per-
sonal contact. Recently, the search strategy for tRCTs
was updated yielding a total of 210 tRCTs.
In STOPIT-3, we will search for and analyze RCTs
(truncated or not sRCTs) published after the publication
of each primary tRCTs. If we have a tRCT with sRCT
that is also a tRCT, each study will be analyzed inde-
pendently and two search strategies will be developed.
This means that we will include this tRCT as a sRCT for
the first tRCT, but it will be also analyzed as a tRCT
itself.
Following the same approach used in STOPIT-1, we
will determine the prevalence of tRCTs reporting having
stopped early for benefit. The methodology of this
present study is summarized in Figure 2.
Literature search
With input from study investigators (MB, GJP, JPD,
MHM) experienced in conducting systematic reviews, a
reference librarian (PJE) will design and execute individual
search strategies for each tRCT included in the database.
These electronic search strategies will use controlled vo-
cabulary and text words taking into account the character-
istics of the population involved, the intervention, and
comparison used. We will not consider the outcomes
assessed in the tRCTs as a part of the search strategy to
ensure high search sensitivity. For each tRCT, we will
search the electronic databases (Ovid MEDLINE, Ovid
Embase, Ovid Cochrane Library, Web of Science, Scopus,
STOPIT- 1
RCTs (1975-2004)
tRCTs
STOPIT- 2
tRCTs vs.
Non tRCTs
Epidemiology of tRCTs: 143 tRCT, 92 were published in high impact
journals. The proportion of all RCTs published in high-impact
journals that were stopped early for benefit increased with time.
Empirical quantification of the average overestimation and its
determinants: 91 tRCTs asking 63 different questions and 424
matching non-truncated RCTs. tRCT over-estimated the effect by
30% independent of the presence of a statistical stopping rule and
the methodological quality of the studies.
Summary of the STOPIT studies
Abbbreviations.- RCT: Randomized controlled trial, sRCT: Subsequent
randomized controlled trial, tRCT: Truncated randomized controlled trial
STOPIT- 3
tRCTs
Epidemiology of sRCTs: 210 tRCT and all the sRCTs available
(truncated or not)
Time
sRCTs
Continued
(similar PICO)
Why were they launched
or continued?
sRCTs
Launched
(similar PICO)
Figure 1 Summary of the STOPIT studies.
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tRCTs through to the present time.
Eligibility criteria
In order to consider a trial as an eligible sRCT it has to
be either: 1) launched (that is, started enrollment) afterthe publication date of a matching tRCT; sRCT may, or
may not, be terminated prematurely for benefit based on
its own data; or 2) ongoing at the time of publication of
the tRCT, and achieving the calculated sample size and
planned study duration after the tRCT publication date.
It does not matter whether the sRCT was stopped early
or not.
As a general approach we will consider trials as sRCTs
of a tRCT if pooling them together in meta-analysis
seems adequate. An example is shown in Figure 3.
Study selection
We will use an online reference management system
(DistillerSR, Ottawa, ON, Canada) for study selection.
Reviewers will first calibrate their judgments using a
small set of reports. Two reviewers will independently
screen for potential eligibility the title and abstract of
each citation that result from the search strategy. We
will obtain the full text version of any citation that either
reviewer deems potentially eligible.
Two reviewers will independently evaluate each full text
for eligibility. We will measure agreement using the kappa
or phi statistics, as appropriate (the latter is appropriate
when the distribution of agreement is extreme). This will
be provided in real-time by the online system. Disagree-
ments will be resolved by discussion or, if necessary, by
third party adjudication. For all eligible sRCTs, during data
extraction, reviewers will judge whether the patients, in-
terventions, comparators, and outcomes match those of
the corresponding tRCT as narrow (very closely matched),
broad (closely matched), or broadest (matched, but appre-
ciable differences). For this purpose we will use the criteria
previously established in STOPIT-2.
Thus, we will classify each element of the sRCT (pa-
tients, interventions, comparators, and outcomes; for the
assessment of outcomes we will consider the outcome
used for stopping the tRCT) as very close (termed as ‘fits
the narrow criteria’), moderately close (termed as ‘fits
the broad criteria’), and less close (termed as ‘fits the
broadest criteria’) relative to the tRCT elements. We will
also check the level of agreement (kappa or phi statis-
tics) for this judgment. Disagreements in relation to
similarity of one level or greater will require adjudication
by a third reviewer [6].
Based on these criteria we will classify each sRCT rela-
tive to its tRCT as: more or less identical; similar, but
not identical; and broadly similar.
This will be a subjective process done in duplicates.
Disagreements will be resolved by consensus or, if neces-
sary, third party arbitration (Figure 4).
Data collection and extraction
We will collect data in pre-piloted standardized elec-
tronic forms designed using the online reference
Identification of tRCT
(STOP IT-2: 210 studies) Search for sRCTs
Retrieval of all included sRCT
Screening
PIC criteria
Assigned
to
reviewers
“Closeness” Assessment
(PICO cirteria)
Data extraction Analysis
Eligible
studies
assigned
Flow chart of the Study of Trial Policy of Interim Truncation (STOPIT)- 3.
Abbreviations.- PIC: Patient population, intervention and control; PICO: Patient population, intervention, control and outcomes; sRCT:
Subsequent randomized controlled trial; tRCT: Truncated randomized controlled trial
STOPIT -3
Figure 2 Flow chart of the STOPIT-3.
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dependently extract the information from each report.
We selected these variables (Additional file 1: Table S1)
based on possible hypothesized explanations of why
sRCT investigators decided to continue or not with the
conduct of their trial, or launched it despite the presence
of a tRCT.
Outcomes of interest and statistical analysis
The main outcome of interest is the proportion and as-
sociated 95% confidence interval (CI) of tRCTs that had
at least one sRCT.
In multivariable regression, we will address the pos-
sible associations between the presence or absence of a
sRCT (dependent variable) and the characteristics of the
tRCTs (independent variables) including: risk of bias,
magnitude of effect, number of events, funding, presence
of DMC, explicit use of a stopping rule, and impact fac-
tor of journal of publication. The rationale for these var-
iables is that increased risk of bias, small number ofevents, conflicts of interest, lack of DMC or stopping
rule, and low journal impact factors are all possible rea-
sons for sRCT investigators to be less convinced of the
tRCT results. We will adjust the analysis by the year of
tRCT publication (more recent tRCTs are expected to
have a lower number of sRCTs, since there would not be
sufficient time for sRCTs to accrue, and previous publi-
cations regarding the dangers of early stopping may have
decreased the number of tRCTs in which early stopping
is at highest risk of misleading overestimates).
Risk of bias assessment
The risk of bias of most of the included tRCTs was
assessed during the development of the previous studies
using the items of the Cochrane risk of bias tool [8]: allo-
cation concealment (documented as central independent
randomization facility or numbered/coded medication
containers prepared and distributed by an independent fa-
cility (for example, pharmacy)); blinding of participants,
care providers, and outcome adjudicators (blinding of
Figure 3 Closeness assessment.
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yes’ when trial report states ‘double blinded’ or ‘placebo
controlled’); loss to follow-up (difference between the
number of participants randomized and the number of
participants with data for the outcome of interest), and ad-
herence to the intention-to-treat principle. We will follow
the same approach for any new or not assessed tRCT.
Optimal information size and the progression of the body
of evidence
We will calculate for each research question (tRCT and
its sRCT) the optimal information size (relative risk re-
duction (RRR) 25%, weighted mean control group event
rate, α = 0.05, β = 0.90) and Lan-DeMets sequential
monitoring boundaries at the time of publication of the
tRCT using all relevant trials published to that point.
We will also calculate the necessary information size to
obtain conclusive evidence of a plausible RRR of 25%,
that is, the difference between the optimal information
size and the actually available information size at the
time of publication of the tRCT. We will check how
close the boundary of the 95% CI of the summary effect
at the time of the tRCT publication is to no effect (that
is, 1 since we will be dealing only with relative risks).
Lastly, we will determine if there is an association be-
tween the number of events and chances of the exist-
ence of sRCTs.In addition, we will estimate the prevalence of trials
stopped early for benefit using the newly found sRCTs
(after STOPIT-1) that were stopped early as the numer-
ator, and all RCTs published in all MEDLINE-indexed
journals or the subset of RCTs published in high impact
journals as the denominator. Therefore, we will be able
to compare the prevalence of stopping early before and
after the publication of STOPIT-1 and 2, and determine
if these publications had an impact on trial conduct.
Sensitivity analysis
We plan to conduct two sensitivity analyses. The first
one will be based on the closeness of the sRCTs to the
research question of the tRCTs (more or less identical;
similar, but not identical; and broadly similar). Consider-
ing that there is no objective method to assess closeness
of research questions it is plausible that investigators of
sRCTs would continue their trial if their question were
less close to the tRCT. We will test the impact of our as-
sumptions it the results using a sensitivity analysis in-
cluding only the sRCT-tRCT pairs with clear identical
research questions according to the closeness classifica-
tion given to each sRCT during the study selection
phase.
The second sensitivity analysis will compare two defi-
nitions of sRCTs based on the timeframes of 6 and 12
months between the publication of the tRCT and the
Figure 4 Final closeness assessment.
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that at least 6 to 12 months are needed to assure that a
sRCT is truly a subsequent trial and not a parallel trial,
which would make it impossible for the investigators to
be aware of the tRCT.
Author contact
We will contact the principal investigators of the sRCTs
to further explore the reasons why they launched or
continued trials after the tRCT. We will use a short,
standardized web-based survey instrument developed
with SurveyMonkey (Palo Alto, CA, USA) (Additional
file 2: Table S2). We will make two attempts by email
per contact author at a 2-week interval. If the author’s
email address is not available we will make contact by
mail or telephone. In an effort to increase our response
rate we will also try to contact both the first and senior
author following the same approach. If after these at-
tempts we do not receive an answer we will try to contact
them (contact, first, and senior authors) by telephone. As
a last resource, we will try to contact the other authors
listed in each publication following the same approach.Reporting
We will report this study in accordance with the recom-
mendations set forth by the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
workgroup [9], and the recommendations developed by
the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) [10]. We will present evi-
dence tables for each tRCT including description of the
population characteristics, interventions, methodological
quality, and main findings.Discussion
STOPIT-1 and 2 described the epidemiology of trials
stopped early for benefit, including how often early stop-
ping occurs, average overestimation of effect estimates,
and its predictors (truncated RCTs having fewer than
500 events). In this systematic review, we will try to
measure the impact of a tRCT on the body of evidence,
and determine specifically the frequency of sRCTs and
determinants of their occurrence. We will try to find the
ideal information size for these trials.
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The strengths of this study include a systematic and ex-
tensive literature search for each of the included tRCTs
performed by an experienced librarian and supported by
methodological experts. We will also contact authors of
sRCTs, and obtain their feedback and rationale. Two re-
viewers with experience in the development of system-
atic reviews will assess each study independently, thus
decreasing the risk of error and strengthening confidence
in the selection process. We have a priori developed this
study protocol and included sensitivity analyses to deter-
mine if the assumptions we made may affect study conclu-
sions to a certain extension.
Limitations include our reliance on published and
indexed publications to identify sRCTs. Considering that
the previous publication of a tRCT may reduce the
chances of a sRCT to be submitted and eventually pub-
lished, we are facing a new potential factor for publica-
tion bias. In addition, a known limitation of STOP-IT 1,
2, and 3 is the inaccuracy of identifying tRCTs, since
truncation is frequently not clearly described in the ab-
stracts or full reports of RCTs [11].
Ethical and data monitoring implications
The results of this systematic review will impact on the
development of future trials and the decision-making
process of DMCs. The ultimate goal of a DMC should be
to share benefits of an effective treatment as soon as there
is sufficient confidence in the magnitude of its effects,
both benefits and harms [1]. Sufficient confidence would
translate into an ethical mandate to offer the intervention
to all patients, and to no longer randomize patients to the
possibility of not receiving the intervention.
For each sRCT which their authors knew about the
existence of previous tRCT on the same research ques-
tion, we can infer that authors agreed that randomizing
patients continues to be ethical. In such instances, we
can conclude that the stopping rule used had serious
limitations. If a large proportion of tRCTs are associated
with sRCTs this would mandate a re-evaluation of the
criteria currently used to judge the appropriateness of
stopping early for benefit.
Public engagement in science
The results of this review will impact on several aspects
of public interest. Many different interests converge into
releasing the results earlier of a study showing signifi-
cant benefits. Institutional review boards and funding
agencies take into account previous research made in an
area before approving a new trial. Following the same
approach, journals should consider previous publications
before accepting a new trial. Therefore, the publication
of a tRCT may slow or prevent future trials answering
the same or a similar question, generating a ‘freezingeffect’. It is possible that our study will identify such a
freezing effect if we find an old tRCT that was not
followed by any sRCTs and the body of evidence
remained inconclusive after the publication of the tRCT
[12]. Inference regarding a freezing effect involves the
assumption that trial publication, continuation, or initi-
ation is driven by the conclusiveness of the body of evi-
dence and ignores other factors that relate to funding
availability, economy, and other temporal trends.
tRCTs are published in higher impact journals and
gain more media attention; therefore, the media and the
public may be impacted more by their results, and they
may have increased confidence in the findings. However,
if we find a large number of sRCTs, this may suggest
that the academic community did not accept the ethical
judgment of trials DMCs and trialists. This would
mandate a re-evaluation of the current stopping criteria
and the confidence the public should have about the
findings.
Conclusion
Given the increasing frequency of tRCTs published in
high impact journals and the fact that these studies may
overestimate the real effect of an intervention, it is im-
portant to evaluate the impact of tRCTs on the body of
evidence. Distortion of the body of evidence can subse-
quently lead to biased systematic reviews, and impact
guideline recommendations and patient care.
Trial status
The systematic review is currently in full text screening
phase. Completion is expected by November 2013.
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